Anixa Biosciences is trading at $2.88, up 7.80% in pre-market, with no clear company-specific catalyst identified. - This compares with the October 13 close of $2.67. - After-hours coverage also noted no clear catalyst; mixed market context does not clearly explain the rise. - October 13 announcements said its ovarian cancer CAR-T therapy inventor will keynote at a November conference and publicized an October 20 investor webinar; neither is a reported clinical or regulatory milestone.